NL-OMON41196已完成不适用
Single-center, open-label, non-randomized study investigating the excretion balance, pharmacokinetics and metabolism of a single oral dose of [14C]-labeled RO5285119 in healthy male subjects - RO5285119 mass balance study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •35-64 yrs, inclusive
- •BMI: 18.0 - 30.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
进行中（未招募）
不适用
A study comparing cholic acid capsules that are not currently available, with cholic acid capsules that are currently available, to check that they are as safe and work just as well in treating children born with a birth defect inherited from their parents, which means that their body cannot make normal bile acidsPatients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004491-10-Outside-EU/EEAAsklepion Pharmaceuticals, LLC16
进行中（未招募）
不适用
An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant TherapyEUCTR2004-004796-11-DEKlinikum Augsburg100
尚未招募
不适用
An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients with Advanced Solid Tumors or Lymphomas, who are Unsuitable For, or Have Failed, Existing TherapiesDrug Metabolism10027656CancerNL-OMON33844Eisai10
尚未招募
不适用
An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 labeled Eribulin Acetate (14C-Eribulin) in Patients with Advanced Solid TumorsDrug metabolism10027656CancerNL-OMON32470Eisai10
进行中（未招募）
不适用
An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusion of cerebral beta-amyloid in patients with probable Alzheimer’s disease compared to healthy volunteers - Safety and efficacy of positron emission tomography imaging with BAY 94-9172 (ZK 6013443)Probable Alzheimer Disease patients compared to Healthy Volunteers. The clinical diagnosis - in Part A made by the investigator, in Part B established by an independent consensus panel of experts in dementia - will serve as the standard of truth and will be based on internationally accepted, validated (diagnostic) criteria and established after comprehensive review of all available clinical, neuro-psychiatric and other relevant data.MedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2007-002256-42-DEBayer Schering Pharma AG438